Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients

Kidney International

Volumn 88, Issue 5, 2015, Pages 1187-1194

  Gupta, Ajay ^a,b   Lin, Vivian ^b   Guss, Carrie ^b   Pratt, Raymond ^b   Ikizler, T Alp ^c   Besarab, Anatole ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Rockwell Medical   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Erythropoiesis stimulating agent; Ferric pyrophosphate citrate; Hemodialysis; Iron

Indexed keywords

ANTIANEMIC AGENT; FERRIC PYROPHOSPHATE; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; DIALYSIS FLUID; PYROPHOSPHORIC ACID DERIVATIVE; TRACE ELEMENT;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTERIOVENOUS FISTULA; ARTHRALGIA; ARTICLE; ASTHENIA; BRADYCARDIA; CHEMICAL COMPOSITION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COUGHING; DIALYSATE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FERRITIN BLOOD LEVEL; HEART DISEASE; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; HYPERVOLEMIA; HYPOTENSION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG EFFECTS; HEMODIALYSIS; METABOLISM; MIDDLE AGED; PROCEDURES;

ADULT; AGED; DIALYSIS SOLUTIONS; DIPHOSPHATES; DOUBLE-BLIND METHOD; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; RENAL DIALYSIS; TRACE ELEMENTS;

EID: 84947611634     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.203     Document Type: Article

References (17)

1. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634.
2. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004; 22: 112-123.
3. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116: 4754-4761.
4. Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014; 29: 263-273.
5. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425-4433.
6. Thomas DW, Hinchliffe RF, Briggs C et al. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013; 161: 639-648.
7. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008; 83: 580-588.
8. Fishbane S, Mathew AT, Wanchoo R. Intravenous iron exposure and outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 2014; 9: 1837-1839.
9. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000.
10. Gupta A, Amin NB, Besarab A et al. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 1999; 55: 1891-1898.
11. Gupta A, Crumbliss AL. Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration? J Lab Clin Med 2000; 136: 371-378.
12. Huebers HA, Finch CA. The physiology of transferrin and transferrin receptors. Physiol Rev 1987; 67: 520-582.
13. Rostoker G, Griuncelli M, Loridon C et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012; 125: 991-9 e1.
14. Kosch M, Bahner U, Bettger H et al. A randomized, controlled parallelgroup trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16: 1239-1244.
15. United States Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2013.
16. Cowart RE, Swope S, Loh TT et al. The exchange of Fe3+ between pyrophosphate and transferrin. Probing the nature of an intermediate complex with stopped flow kinetics, rapid multimixing, and electron paramagnetic resonance spectroscopy. J Biol Chem 1986; 261: 4607-4614.
17. Cervato G, Viani P, Gatti P et al. Further studies on the antioxidant role of pyrophosphate in model membranes. Chem Phys Lipids 1993; 66: 87-92.